Table 2.
Characteristics evaluated during the 12-month baseline period before the initiation of the index agent among patients with CD.
| Baseline period | Biologic cohort N = 5107 |
Conventional cohort N = 6072 |
|---|---|---|
| Age, mean ± SD | 43.9 ± 15.4 | 50.5 ± 16.7 |
| Female, N (%) | 2860 (56.0%) | 3604 (59.4%) |
| Region of residence, N (%) | ||
| Northeast | 540 (10.6%) | 724 (11.9%) |
| Midwest | 1625 (31.8%) | 1629 (26.8%) |
| South | 2052 (40.2%) | 2530 (41.7%) |
| West | 881 (17.3%) | 1171 (19.3%) |
| Unknown | 9 (0.2%) | 18 (0.3%) |
| Insurance plan type, N (%) | ||
| Medicare | 639 (12.5%) | 1562 (25.7%) |
| Commercial insurance | 4468 (87.5%) | 4510 (74.3%) |
| Year of index date | ||
| 2004 | 109 (2.1%) | 264 (4.3%) |
| 2005 | 276 (5.4%) | 532 (8.8%) |
| 2006 | 223 (4.4%) | 427 (7.0%) |
| 2007 | 288 (5.6%) | 432 (7.1%) |
| 2008 | 357 (7.0%) | 479 (7.9%) |
| 2009 | 400 (7.8%) | 464 (7.6%) |
| 2010 | 436 (8.5%) | 454 (7.5%) |
| 2011 | 386 (7.6%) | 487 (8.0%) |
| 2012 | 367 (7.2%) | 460 (7.6%) |
| 2013 | 406 (7.9%) | 473 (7.8%) |
| 2014 | 450 (8.8%) | 467 (7.7%) |
| 2015 | 597 (11.7%) | 490 (8.1%) |
| 2016 | 609 (11.9%) | 447 (7.4%) |
| 2017 | 203 (4.0%) | 196 (3.2%) |
| Time from first observed CD diagnosis to index date, months, mean ± SD | 28.2 ± 24.7 | 23.6 ± 23.0 |
| Claim-derived moderate-to-severe patient statusa, N (%) | 3313 (64.9%) | 2406 (39.6%) |
| Quan-CCI, mean ± SD | 0.75 ± 1.3 | 1.0 ± 1.7 |
| IBD-related surgeries, N (%) | 418 (8.2%) | 373 (6.1%) |
| Comorbidities (top 5), N (%) | ||
| Pain | 2990 (58.5%) | 3162 (52.1%) |
| Cardiovascular disease | 2323 (45.5%) | 3212 (52.9%) |
| Anemia | 1767 (34.6%) | 1793 (29.5%) |
| Fatigue | 1093 (21.4%) | 1272 (20.9%) |
| Depression | 876 (17.2%) | 938 (15.4%) |
| Medication use | ||
| Corticosteroids | 3688 (72.2%) | 3395 (55.9%) |
| Opioids | 3055 (59.8%) | 3235 (53.3%) |
| 5-ASA | 2311 (45.3%) | 1738 (28.6%) |
| Immunomodulators | 2212 (43.3%) | 1680 (27.7%) |
| Antibiotics | 2005 (39.3%) | 645 (10.6%) |
| Biologics (other than index agent) | 953 (18.7%) | —b |
| Healthcare costs (USD 2019), mean ± SD | 34 084 ± 38 697 | 25 130 ± 53 494 |
| Prescription drug costs (including biologic costs) | 7407 ± 12 121 | 3689 ± 7035 |
| Total medical costs (including biologic costs) | 26 677 ± 36 350 | 21 441 ± 52 310 |
Abbreviations: 5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; IBD, inflammatory bowel disease; Quan-CCI, Quan-Charlson Comorbidity Index; SD, standard deviation.
Claim-derived moderate-to-severe patients defined as patients with any of the following indicator(s): patients receiving biologics, patients receiving immunomodulators, patients receiving corticosteroids (≥90 days of continuous use), patients with IBD-related hospitalizations (including IBD-related surgeries).
Per design, patients in the conventional cohort could not use biologics during their baseline.